Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Issuances (2016 - 2025)

Integra Lifesciences Holdings' Long-Term Debt Issuances history spans 14 years, with the latest figure at $49.7 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances rose 40.4% year-over-year to $49.7 million; the TTM value through Dec 2025 reached $720.7 million, up 48.14%, while the annual FY2025 figure was $720.7 million, 48.14% up from the prior year.
  • Long-Term Debt Issuances for Q4 2025 was $49.7 million at Integra Lifesciences Holdings, down from $603.7 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $603.7 million in Q3 2025 and bottomed at $600000.0 in Q1 2021.
  • The 5-year median for Long-Term Debt Issuances is $12.5 million (2021), against an average of $71.9 million.
  • The largest annual shift saw Long-Term Debt Issuances tumbled 99.65% in 2021 before it surged 3532.35% in 2024.
  • A 5-year view of Long-Term Debt Issuances shows it stood at $12.0 million in 2021, then crashed by 46.06% to $6.5 million in 2022, then soared by 180.0% to $18.2 million in 2023, then soared by 94.51% to $35.4 million in 2024, then soared by 40.4% to $49.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Long-Term Debt Issuances are $49.7 million (Q4 2025), $603.7 million (Q3 2025), and $12.9 million (Q2 2025).